Endocrinology

Shah discusses the potential of GLP-1 receptor agonists as adjunctive therapy in type 1 diabetes, from glycemic control to cardiometabolic risk.

Mechanick discusses the importance of dietary interventions in endocrinology and highlights the need for further education and awareness of metabolic function.

Galindo describes how CKM may transform diabetes care by enabling real-time insights, improving DKA prevention, and advancing metabolic understanding.

Recent data presented at AACE 2026 have indicated the efficacy of GLP-1 RA treatment in reducing risk of diabetic retinopathy, renal disease, and others.

A recent study presented at AACE 2026 has displayed the IGF-1R’s capacity for improving proptosis and disease activity in patients with poorly-controlled TED.

RCTs show intermittent fasting and calorie restriction yield similar HbA1c and cardiometabolic outcomes in type 2 diabetes, with modest, nonsignificant weight differences.

Results from the 52-week open-label extension trial highlight strong safety and efficacy outcomes with lonapegsomatropin in adults with growth hormone deficiency.

Sood discusses the FDA expansion of teplizumab to children as young as age 1 with stage 2 T1D and the implications for early intervention and delaying disease progression.

Propensity-matched data link empagliflozin to lower risk of CV events, AKI, and other outcomes versus dapagliflozin in type 2 diabetes.

A recent presentation at AACE 2026 highlights the drastically increased risk of mortality, sepsis, diabetic ketoacidosis, and recurrent acute pancreatitis after GLP-1 initiation.

A recent study from AACE 2026 has indicated the value of bariatric surgery in adults with type 1 diabetes – and emphasized the need for closer perioperative management.

Teplizumab is now approved to treat stage 2 type 1 diabetes in kids 1 year and older.

Beck discusses the recently presented results of INHALE-1, in which technosphere insulin failed to prove noninferiority to RAA but had no pulmonary effects.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Experts discuss how metabolic and hormonal factors in women influence MASLD risk, progression, and potential long-term outcomes.

Beck discusses a recent analysis of the phase 4 trial comparing TI and degludec against standard treatment, highlighting the need for individualized titration.

View slated expert interviews and 7 clinical trials to watch at AACE Annual Meeting 2026.

Results from the largest and longest trial of orforglipron to date have displayed the drug’s efficacy in reducing all-cause cardiovascular death and MACE incidence.

Bacino highlights the recently approved treatment’s safety data and emphasizes the likelihood of increased adherence due to longer intervals between administration.

Nissen discusses his post-hoc analysis of the SURPASS-CVOT trial, comparing the 2 drugs for a 6-component composite endpoint of cardiorenal outcomes.

Catch up on FDA decisions, new GLP-1 agonists, and more.

March 2026 endocrinology updates include key FDA approvals, advances in diabetes and obesity therapies, and innovations in insulin delivery and rare disease care.

Jessica Castle, MD, joins the show to give a peek behind the curtain at Dexcom’s latest advancements in CGM technology.

A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.

Amgen has announced positive topline results from their phase 3 trial comparing teprotumumab-trbw – administered via an on-body injector – to placebo.